戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                 Adjusted VE was similar in adults born before 1950, presumed primed by na
2 erative complications (P = .17) and interventions (P = .10) was similar in all groups.
3 1 participants were enrolled; global retention in the study was similar in both arms (56% overall, 58% in the systematic,
4 r in South Africa than Malawi, in adjusted models mortality was similar in both countries (hazard ratio, 0.9; P = .729).
5 ency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]).
6                        The number of serious adverse events was similar in both groups and unrelated to the intervention
7 he patients during follow-up, and the extent of improvement was similar in both study groups.
8                           The overall 30-day mortality rate was similar in both time periods (1.8% versus 1.4%, P=0.457).
9 rall complexity of the systemic inflammatory/immune network was similar in IRF3-KO versus WT septic mice, although the te
10  to 0.67 in smaller LVs (P = 0.03), whereas PET performance was similar in larger and smaller LVs (AUC, 0.79 vs. 0.77, P
11                            In the second survey, prevalence was similar in men and women, but an increased prevalence was
12                                              Mortality risk was similar in participants with >0.5-1.0 nmol/L compared wit
13                                                  Recurrence was similar in patients receiving PMRT compared to those that
14                       Death within 28 days of ICU admission was similar in SOT and non-SOT patients (40% and 43%, respect
15 s not significantly different in TRPC1/6(-/-) pmLF and ROCE was similar in STIM1/2-deficient pmLF compared to Wt cells.
16       Compared to sigmoidoscopy, the detection rate for CRC was similar in the first FIT round (0.25% vs 0.27%; OR, 0.92;
17 nts, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV555 group and the placebo group (19%
18 ntage of participants with local or systemic adverse events was similar in the two groups.
19         The incidence of serious adverse events was low and was similar in the vaccine and placebo groups.
20           Overall, apparent ileal digestibility of nitrogen was similar in vitro and in vivo and the differences between
21                                                  The groups were similar in age and risk factors.
22                                  Cases and control subjects were similar in age, sex, and cancer type.
23 ] in 300 mg S44819 group, and 90 [70-100] in placebo group) were similar in all groups.
24           Hepatic fat, insulin sensitivity index, and SCD-1 were similar in black women and lower than in whites, regardl
25 k subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms.
26                                          Secondary outcomes were similar in both groups and include median time to oral a
27        Preoperative CV, percent of hexagonal cells, and CCT were similar in both groups and remained stable.
28                                        Nutritional outcomes were similar in both groups.
29                        However, surgical complication rates were similar in both groups.
30                           Task-dependent neural modulations were similar in both regions.
31  a carcass, whilst females that had cared for a large brood were similar in competitive ability to virgin females.
32  of proteins in the mechanistic target of rapamycin pathway were similar in control and IUGR skeletal muscle homogenate.
33                                                 The results were similar in inverse probability of treatment and censorin
34                        Pretransplant, M-MDSC, and monocytes were similar in KTRs and healthy volunteers.
35 P and mitochondrially encoded and synthesized protein mtCO1 were similar in mitochondria from YAC128 mice and their wild-
36                                                     Results were similar in multiple sensitivity analyses.
37 stidine uptake and system L amino acid transporter activity were similar in sarcolemmal membranes isolated from control a
38  poorer condition than fish showing maturation tactics, but were similar in size to unassigned fish.
39                  Cumulative rates of serious adverse events were similar in TAK-003 (4.0%) and placebo (4.8%) recipients,
40 t last follow-up, eyes that returned to OR and control eyes were similar in terms of mean intraocular pressure (IOP), the
41                        We demonstrate that lions and wolves were similar in that group-level factors, such as number of g
42                                                      Groups were similar in the incidence of reoperation, vascular thromb
43                                                     Results were similar in the intention-to-treat analysis.
44                                    Baseline characteristics were similar in the intervention (n = 65) and control (n = 67
45                                           Bayley III scores were similar in the IVB and control groups, except for a mino
46 istics, including severity of pain and level of disability, were similar in the two groups.
47                                    Other secondary outcomes were similar in the two groups.
48                       The rates of hospitalization or death were similar in the two groups.
49                                              Adverse events were similar in the two trial groups, with no notable hyperse
50                                                  Predictors were similar in women aged 18-49.